News

PCA-2 (Purkinje Cell Antibody 2) und Purkinje Line Assay

AVAILABLE ON REQUEST

The detection of PCA-2 autoantibodies is protected by patents. ravo as the sole licensee offers Line Assays for the detection of PCA-2 autoantibodies worldwide exclusively.

PCA-2 Line Assay

Line Assay for the detection of paraneoplastic PCA-2 autoantibodies to the Microtubule-associated protein MAP1B

PCA-2 autoantibodies are known for almost two decades. These autoantibodies bind to a 280 kDa protein in dendrites and somata of Purkinje cells showing a typical staining pattern.

As underlying antigen MAP1B, a member of the microtubule-associated protein family (MAP) has been identified.

Autoantibodies to MAP1B often co-exist with autoantibodies to GAD 65, HuD, CV2 (CRMP5), Amphiphysin and SOX1 and also with autoantibodies to surface proteins like VGKC and VGCC (Voltage Gated Potassium resp. Calcium Channels).

Purkinje Line Assay

Line Assay for the detection of paraneoplastic PCA-2 autoantibodies anti-Yo (PCA-1), anti- MAP1B (PCA-2), anti-Tr (DNER) and anti-Protein Kinase C ɣ (PKCɣ)

Table*:	Paraneoplastic neurological syndromes	Most frequently associated tumors
Anti-Yo-Antibodies (PCA-1, Purkinje-cell-antibody 1)	Progressive cerebellar degeneration Neuropathy Very rare: Opsoclonus-Myoclonus Syndrome, brainstem encephalitis, myelopathy	Ovarian cancer Uterus cancer Breast cancer Cancer of the tuba uterina In single cases: lymphoma, adenocarcinoma of the lung and the parotis
Anti-Tr (DNER)-Antibodies	Progressive cerebellar degeneration with occasional dysarthrie and nystagamus Rare: Limbic encephalitis	Hodgkin Lymphoma Non- Hodgkin Lymphoma
Anti-PKCγ-Antibodies	Cerebellar degeneration	Non-small-cell-lung cancer Adenocarcinoma
Anti-MAP1B-Antibodies (PCA-2, Purkinje-cell-antibody 2)	Cerebellar degeneration Limbic encephalitis Brainstem encephalitis Lambert-Eaton myasthenia syndrome (LEMS) Peripheral and autonomic neuropathy	Small-cell-lung cancer Breast cancer

* Source: Neurologie compact, 9. Auflage